ClinicalTrials.gg
CompletedNCT02888964ACTIMUpdated Jul 6, 2026

Pioglityazone and Imatinib for CML Patients

A Phase 2 interventional study of Add-on therapy in Leukemia, Myeloid, Chronic-Phase, sponsored by Versailles Hospital. Completed at 9 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Versailles Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Leukemia, Myeloid, Chronic-Phase with a site in France — 5 open to participants now, 7 under way, 1 of them phase 3. Leukemia, Myeloid, Chronic-Phase · France.

Enrollment
23rd of 23
27 · median 84
Started
2009
with 1 other
Phase 2
9 of 26
none open now
Registered
19th of 26
by date
Lead sponsor
2 of 26
Versailles Hospital

Among the 26 studies in Leukemia, Myeloid, Chronic-Phase with a site in France, this one is the 23rd largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2009, is one of 9 in phase 2, and was the 19th registered.

Leukemia, Myeloid, Chronic-Phase

439 studies on the registry are indexed under Leukemia, Myeloid, Chronic-Phase; 27 are open to participants now.

Browse Leukemia, Myeloid, Chronic-Phase studies →

Open to participants now

5 of the 26 studies in Leukemia, Myeloid, Chronic-Phase with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 21 Leukemia, Myeloid, Chronic-Phase studies recruiting now, 14 (67%) set no upper age limit and 5 (24%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Leukemia, Myeloid, Chronic-Phase with a site in France, or all of them as a file.
02

Study summary

This project is a Phase II clinical trial that aims at evaluating efficacy and tolerance of the combination of pioglitazone (Actos®) and imatinib mesylate (STI571, CGP57148, Gleevec®) in patients with Chronic Myelogenous Leukemia (CML) in stable major molecular response (i.e. a BCRABL/ABL ratio assessed by RTQ-PCR equal to or lower than 0.1% according to the European Leukemia Net recommendations) after at least 2 years of therapy with imatinib.

Imatinib mesylate (Gleevec®) is the gold standard for the treatment of CML in chronic phase (O Brian et al. 2003, Druker et al. 2006). Despite a high efficacy of the drug, CML is not eradicated by imatinib alone in almost any of the patients.

Treatment discontinuation in patients treated by imatinib and in complete molecular remission for more than 2 years yield molecular relapses within 6 months in half of the patients,indicating the persistence of CML progenitor cells. STAT5 expression is required for CML stem cell engraftment and expansion in mouse models. STAT5 is the target of the dysregulated activity of BCR-ABL in CML.

Recently, Stephane Prost et al. demonstrated that PPAR-γ is a negative regulator of STAT5A and STAT5B gene expression. Data obtained suggest that PPAR-γ agonists may have potential therapeutic value in reversing myeloproliferative disorders. On the basis of our preclinical studies, we went ahead and administered pioglitazone to one patient who suffered from both diabetes type II and CML with residual disease after continuous treatment with Gleevec. The amount of BCR-ABL transcript detected by QPCR decreased dramatically during the first 3 months of combined (Gleevec + ACTOS) therapy to become undetectable thereafter until 9 months post-treatment, the latest time point assessed. This striking anecdotal result now forms the rationale for filing this formal Phase II clinical trial application.

03

Conditions studied

  • Leukemia, Myeloid, Chronic-Phase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient aged 18y or more
  2. Signed
  3. Patient with Philadelphia chromosome positive chronic phase CML and M BCR-ABL transcript positivity
  4. Treatment with imatinib for more than 2 years
  5. No dose modification of imatinib within the last 3 months
  6. Complete cytogenetic response on the last cytogenetic analysis within the last 12 months
  7. Major molecular remission without complete molecular remission
  8. grade 0 to 2
  9. et SGPT ≤ 2.5 N
  10. in serum ≤ 1.5 N
  11. Women of (WOCBP) must be using an adequate method of

Exclusion criteria

Exclusion Criteria:

  1. Participation in another clinical trial with any investigative drug within 30 days prior to study enrollment
  2. Prior history of hematopoietic stem cell transplantation (autologous or allogenic)
  3. Patient requiring anti-diabetic medication
  4. Cardiovascular disease:

    • Stage I to IV congestive heart failure (CHF) as determined by the (NYHA) classification system for heart failure
    • Myocardial infarction within the previous 6 months
    • Symptomatic cardiac arrhythmia requiring treatment
  5. Grade III or IV fluid retention
  6. Known osteoporosis with therapy
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    ACTOS treatment

    Imatinib mesylate at the same daily dose and pioglitazone as add-on therapy at 30 mg/d during 2 months and then 45 mg/d in the absence of serious adverse events

    Drug: Add-on therapy

Interventions

  • DrugAdd-on therapy

    Pioglitazone therapy

06

What researchers measure

Primary outcomes

  1. The rate of patients achieving a complete molecular response (Sensitivity 10-5 or Bcr Abl/Abl ratio < 0.001 %) 24 weeks after the initiation of pioglitazone, confirmed on by a second determination 2 months later.

    Time frame: 26 weeks

Secondary outcomes

  1. Adverse events

    Time frame: 5 years

  2. Duration of the complete molecular response

    Time frame: 5 years

  3. The rate of patients achieving a complete molecular response (Sensitivity 10-5 or Bcr-Abl/Abl ratio < 0.001 %)

    Time frame: 14 months

  4. Survival

    Time frame: 5 years

  5. Progression free survival

    Time frame: 5 years

07

Study locations

9 sites
  • CHR Annecy
    Annecy, France
  • Institut Bergonié
    Bordeaux, France
  • CH Versailles
    Le Chesnay, France
  • CHU Lille
    Lille, France
  • IPC
    Marseille, France
  • CHU archet 1
    Nice, France
  • St Louis
    Paris, France
  • CHU Poitiers
    Poitiers, France
  • CHU Purpan
    Toulouse, France
08

References and documents

Publications

  • Rousselot P, Prost S, Guilhot J, Roy L, Etienne G, Legros L, Charbonnier A, Coiteux V, Cony-Makhoul P, Huguet F, Cayssials E, Cayuela JM, Relouzat F, Delord M, Bruzzoni-Giovanelli H, Morisset L, Mahon FX, Guilhot F, Leboulch P; French CML Group. Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study. Cancer. 2017 May 15;123(10):1791-1799. doi: 10.1002/cncr.30490. Epub 2016 Dec 27. PubMed 28026860 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Feb 2012 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2016
First posted
Sep 5, 2016
Start
Dec 2009
Primary completionActual
Feb 2012
CompletionActual
Feb 2016
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02888964
Lead sponsor
Versailles Hospital
Responsible party
Philippe ROUSSELOT (Study Coordinator, Versailles Hospital) — Principal investigator
First posted
Sep 5, 2016
Start date
Dec 2009
Primary completion
Feb 2012
Completion
Feb 2016
Last update
Jul 6, 2026

Study contacts

Rousselot Philippe, MD
principal investigator · CH Versailles

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion